Lipid nanoparticles (LNPs) have emerged as a powerful non-viral carrier for drug delivery.
With the prevalence of respiratory diseases, particularly highlighted by the current COVID-19 …

Current management of severe asthma relying either on guidelines (bulk approach) or on
disease phenotypes (stratified approach) did not improve the burden of the disease. Several …

Asthma is a complex heterogeneous disease caused by gene–environment interactions.
Although numerous genome-wide association studies have been conducted, these …

Recognition of phenotypic variability in pediatric asthma allows for a more personalized
therapeutic approach. Knowledge of the underlying pathophysiological and molecular …

As costs of next-generation sequencing decrease, identification of genetic variants has far
outpaced our ability to understand their functional consequences. This lack of understanding …

Asthma is a chronic respiratory disease that affects 339 million people worldwide and has a
considerable impact on the pediatric population. Asthma symptoms can be controlled by …

Multidrug resistance–associated protein 1 (adenosine triphosphate–binding cassette
subfamily C member 1 [ABCC1]) is abundantly expressed at the lung epithelial barrier …

Beta‐blockers are widely used medications for a variety of indications, including heart
failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in …

There is a large interindividual variability in response to ICSs in asthma. About 70% of the
variance in ICS response is likely due at least partially to genetically determined …

The prevalence and incidence of asthma are increasing globally because of genetic and
environmental influences. Prevalence of asthma in the Gulf has been reported to range from …